All Oncology News

Pembrolizumab Significantly Improves EFS as Neoadjuvant, Adjuvant Therapy in High-Risk, Early-Stage TNBC

May 13th 2021

Neoadjuvant pembrolizumab in combination with chemotherapy followed by adjuvant pembrolizumab monotherapy resulted in a significant improvement in event-free survival and pathologic complete response vs neoadjuvant chemotherapy alone in patients with high-risk, early-stage triple-negative breast cancer.

Dr. Anees Chagpar Named 2021 ASCO Fellow

May 13th 2021

Anees Chagpar, MD, MBA, MPH, FACS, FRCS(C), Professor of Surgery (Oncology) and a member of the Cancer Prevention and Control Research Program at Yale Cancer Center was named a Fellow of the American Society of Clinical Oncology.

Reaching Conclusions From Limited Data Holds Pitfalls

May 13th 2021

The challenges of assessing COVID-19 vaccines shows that events in the real world may differ from those of a formal objective scientific analysis, especially in a setting where such evaluations of necessity involve very small numbers.

Ixazomib/Ibrutinib Combo Could Enhance Single-Agent BTK Inhibitor Efficacy in Relapsed/Refractory MCL

May 13th 2021

The ongoing, phase 1/2 PrE0404 trial is evaluating the combination of ixazomib and ibrutinib in patients with relapsed/refractory mantle cell lymphoma with the goal of improving upon single-agent BTK inhibitor therapy in this patient population.

Off-the-Shelf Immunotherapy ADXS-504 Under Evaluation in Biochemically Recurrent Prostate Cancer

May 12th 2021

Columbia University Irving Medical Center will partner with Advaxis, Inc. to fund a phase 1 clinical trial that seeks to examine the novel off-the-shelf neoantigen immunotherapy agent ADXS-504 in patients with biochemically recurrent prostate cancer.

Whole-Genome Sequencing in Smoldering Myeloma and MGUS Could Predict Outcomes

May 12th 2021

Ola Landgren, MD, PhD, and Francesco Maura, MD, discuss their research with whole-genome sequencing in patients with precursor conditions, and spotlight next steps for research.

Upcoming Live Broadcast to Feature Recent Data and Case Study in ALK+ Metastatic NSCLC

May 12th 2021

Personalized, Adaptable Treatment Strategies May Improve Survival in Metastatic Gastroesophageal Cancer

May 12th 2021

Offering patients with metastatic gastroesophageal tumors a more personalized and adaptable treatment approach using monoclonal antibodies matched to genetic profiles in combination with chemotherapy may result in higher rates of survival compared with historic controls.

High Pretreatment ctDNA Levels Correlate With Short Diagnosis-to-Treatment Intervals in DLBCL

May 12th 2021

Pretreatment circulating tumor DNA levels were found to more objectively measure disease burden compared with diagnosis-to-treatment intervals in patients with diffuse large B-cell lymphoma and can therefore be used to quantify and mitigate selection bias in prospective DLBCL clinical trials.

Next-Generation Tissue Factor–Targeting ADC XB002 to be Examined in Several Solid Tumors

May 12th 2021

The safety, tolerability, pharmacokinetics, and preliminary antitumor activity of the novel agent XB002 is set to be examined in an upcoming phase 1 clinical trial that is expected to begin the second quarter of 2021.